Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995–2013: Findings from Texas and national SEER areas

Shuangshuang Fu, Michael Wang, Ruosha Li, David R Lairson, Bo Zhao, Xianglin L Du

Research output: Contribution to journalArticle

Abstract

Background: Over the past 20 years, many novel agents and treatment regimens have been developed to treat mantle cell lymphoma (MCL). This study aimed to determine the impact of these new regimens on the survival of MCL patients from 1995 to 2013. Methods: All newly diagnosed adult MCL patients in the Surveillance, Epidemiology, and End Results (SEER) and Texas Cancer Registry (TCR) databases were included. Patients were grouped into 4 calendar periods based on the time when new novel agents became available: chemotherapy-only (1995–1998, P1), rituximab + chemotherapy (1999–2004, P2), bortezomib and HyperCVAD (2005–2008, P3), bendamustine and Nordic regimen (2009–2013, P4). Associations between these time periods and survival outcomes were analyzed using the Kaplan-Meier method and Cox proportional hazard regressions. Results: A total of 7,555 SEER patients and 2,055 TCR patients were identified. All-cause mortality rates decreased significantly from 1995 to 2013 (SEER, P < 0.001; TCR, P = 0.03). Multivariable analysis of SEER data showed that the risk of MCL-specific death decreased significantly over the study period with hazard ratios of 0.82 (P2 vs. P1), 0.66 (P3 vs. P1), and 0.58 (P4 vs. P1) (P < 0.0001). Similar results were observed for TCR data (P < 0.0001). In an analysis stratified by tumor stage, only patients with advanced- stage tumors showed a significantly decreased risk of death in both SEER (P < 0.0001) and TCR (P = 0.002) datasets. Conclusion: Survival outcome for MCL patients improved from 1995 to 2013, especially for patients with advanced-stage tumors, potentially reflecting the impact of the introduction of novel agents and new therapeutic regimens.

LanguageEnglish
Pages89-97
Number of pages9
JournalCancer Epidemiology
Volume58
DOIs
StatePublished - Feb 1 2019

Fingerprint

Mantle-Cell Lymphoma
Epidemiology
Survival
Registries
Neoplasms
Drug Therapy
Databases
Mortality
Therapeutics

Keywords

  • Mantle cell lymphoma
  • Novel agents and new regimens
  • SEER
  • Survival
  • Texas

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Cancer Research

Cite this

Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995–2013 : Findings from Texas and national SEER areas. / Fu, Shuangshuang; Wang, Michael; Li, Ruosha; Lairson, David R; Zhao, Bo; Du, Xianglin L.

In: Cancer Epidemiology, Vol. 58, 01.02.2019, p. 89-97.

Research output: Contribution to journalArticle

Fu, Shuangshuang ; Wang, Michael ; Li, Ruosha ; Lairson, David R ; Zhao, Bo ; Du, Xianglin L. / Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995–2013 : Findings from Texas and national SEER areas. In: Cancer Epidemiology. 2019 ; Vol. 58. pp. 89-97.
@article{0fa9efc8bcfb4f3ca979440664d0c71e,
title = "Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995–2013: Findings from Texas and national SEER areas",
abstract = "Background: Over the past 20 years, many novel agents and treatment regimens have been developed to treat mantle cell lymphoma (MCL). This study aimed to determine the impact of these new regimens on the survival of MCL patients from 1995 to 2013. Methods: All newly diagnosed adult MCL patients in the Surveillance, Epidemiology, and End Results (SEER) and Texas Cancer Registry (TCR) databases were included. Patients were grouped into 4 calendar periods based on the time when new novel agents became available: chemotherapy-only (1995–1998, P1), rituximab + chemotherapy (1999–2004, P2), bortezomib and HyperCVAD (2005–2008, P3), bendamustine and Nordic regimen (2009–2013, P4). Associations between these time periods and survival outcomes were analyzed using the Kaplan-Meier method and Cox proportional hazard regressions. Results: A total of 7,555 SEER patients and 2,055 TCR patients were identified. All-cause mortality rates decreased significantly from 1995 to 2013 (SEER, P < 0.001; TCR, P = 0.03). Multivariable analysis of SEER data showed that the risk of MCL-specific death decreased significantly over the study period with hazard ratios of 0.82 (P2 vs. P1), 0.66 (P3 vs. P1), and 0.58 (P4 vs. P1) (P < 0.0001). Similar results were observed for TCR data (P < 0.0001). In an analysis stratified by tumor stage, only patients with advanced- stage tumors showed a significantly decreased risk of death in both SEER (P < 0.0001) and TCR (P = 0.002) datasets. Conclusion: Survival outcome for MCL patients improved from 1995 to 2013, especially for patients with advanced-stage tumors, potentially reflecting the impact of the introduction of novel agents and new therapeutic regimens.",
keywords = "Mantle cell lymphoma, Novel agents and new regimens, SEER, Survival, Texas",
author = "Shuangshuang Fu and Michael Wang and Ruosha Li and Lairson, {David R} and Bo Zhao and Du, {Xianglin L}",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.canep.2018.12.002",
language = "English",
volume = "58",
pages = "89--97",
journal = "Cancer Epidemiology",
issn = "1877-7821",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995–2013

T2 - Cancer Epidemiology

AU - Fu, Shuangshuang

AU - Wang, Michael

AU - Li, Ruosha

AU - Lairson, David R

AU - Zhao, Bo

AU - Du, Xianglin L

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Background: Over the past 20 years, many novel agents and treatment regimens have been developed to treat mantle cell lymphoma (MCL). This study aimed to determine the impact of these new regimens on the survival of MCL patients from 1995 to 2013. Methods: All newly diagnosed adult MCL patients in the Surveillance, Epidemiology, and End Results (SEER) and Texas Cancer Registry (TCR) databases were included. Patients were grouped into 4 calendar periods based on the time when new novel agents became available: chemotherapy-only (1995–1998, P1), rituximab + chemotherapy (1999–2004, P2), bortezomib and HyperCVAD (2005–2008, P3), bendamustine and Nordic regimen (2009–2013, P4). Associations between these time periods and survival outcomes were analyzed using the Kaplan-Meier method and Cox proportional hazard regressions. Results: A total of 7,555 SEER patients and 2,055 TCR patients were identified. All-cause mortality rates decreased significantly from 1995 to 2013 (SEER, P < 0.001; TCR, P = 0.03). Multivariable analysis of SEER data showed that the risk of MCL-specific death decreased significantly over the study period with hazard ratios of 0.82 (P2 vs. P1), 0.66 (P3 vs. P1), and 0.58 (P4 vs. P1) (P < 0.0001). Similar results were observed for TCR data (P < 0.0001). In an analysis stratified by tumor stage, only patients with advanced- stage tumors showed a significantly decreased risk of death in both SEER (P < 0.0001) and TCR (P = 0.002) datasets. Conclusion: Survival outcome for MCL patients improved from 1995 to 2013, especially for patients with advanced-stage tumors, potentially reflecting the impact of the introduction of novel agents and new therapeutic regimens.

AB - Background: Over the past 20 years, many novel agents and treatment regimens have been developed to treat mantle cell lymphoma (MCL). This study aimed to determine the impact of these new regimens on the survival of MCL patients from 1995 to 2013. Methods: All newly diagnosed adult MCL patients in the Surveillance, Epidemiology, and End Results (SEER) and Texas Cancer Registry (TCR) databases were included. Patients were grouped into 4 calendar periods based on the time when new novel agents became available: chemotherapy-only (1995–1998, P1), rituximab + chemotherapy (1999–2004, P2), bortezomib and HyperCVAD (2005–2008, P3), bendamustine and Nordic regimen (2009–2013, P4). Associations between these time periods and survival outcomes were analyzed using the Kaplan-Meier method and Cox proportional hazard regressions. Results: A total of 7,555 SEER patients and 2,055 TCR patients were identified. All-cause mortality rates decreased significantly from 1995 to 2013 (SEER, P < 0.001; TCR, P = 0.03). Multivariable analysis of SEER data showed that the risk of MCL-specific death decreased significantly over the study period with hazard ratios of 0.82 (P2 vs. P1), 0.66 (P3 vs. P1), and 0.58 (P4 vs. P1) (P < 0.0001). Similar results were observed for TCR data (P < 0.0001). In an analysis stratified by tumor stage, only patients with advanced- stage tumors showed a significantly decreased risk of death in both SEER (P < 0.0001) and TCR (P = 0.002) datasets. Conclusion: Survival outcome for MCL patients improved from 1995 to 2013, especially for patients with advanced-stage tumors, potentially reflecting the impact of the introduction of novel agents and new therapeutic regimens.

KW - Mantle cell lymphoma

KW - Novel agents and new regimens

KW - SEER

KW - Survival

KW - Texas

UR - http://www.scopus.com/inward/record.url?scp=85057875668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057875668&partnerID=8YFLogxK

U2 - 10.1016/j.canep.2018.12.002

DO - 10.1016/j.canep.2018.12.002

M3 - Article

VL - 58

SP - 89

EP - 97

JO - Cancer Epidemiology

JF - Cancer Epidemiology

SN - 1877-7821

ER -